All treatments
Treatment
Placebo pMDI to match Budesonide/Formoterol Fumarate pMDI clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler (MDI) Relative to Budesonide and Formoterol Fumarate MDI and Symbicort® pressurised MDI in Adult and Adolescent Participants with Inadequately Controlled Asthma (KALOS)
This study is testing a new inhaler for adults with asthma that isn't well controlled. It compares a new triple-medicine inhaler to existing ones to see if it works better at preventing asthma attacks and improving breathing over 24-52 weeks.
For: Severe and inadequately controlled asthmaSpain · Romania · Hungary - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler (MDI) Relative to Budesonide and Formoterol Fumarate MDI and Symbicort® pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma (LOGOS)
This study is looking at new inhalers for adults with asthma that isn't well-controlled. It aims to see if a new combination inhaler works better than current ones to improve breathing and reduce asthma attacks.
For: Severe and inadequately controlled asthmaPortugal · Greece · Germany